undamentalytics Newsletter
Sign in

Cosmos Health Inc. key statistics and ratios

In fiscal 2025, Cosmos Health Inc. had return on equity of -89.1% and a net margin of -29.3%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Net margin27.3%79.1%<−999%−8.9%−20.7%−24.4%−8.3%1.5%−14.2%−27.5%−34.7%−29.7%−29.3%−33.1%
Return on equity—————————−63.3%−49.2%−53.4%−89.1%−124.8%
Return on assets28.4%149.2%−169.5%−31.8%−90.0%−57.8%−14.8%2.4%−17.1%−23.5%−27.7%−26.9%−32.0%−38.4%
Effective tax rate13.9%14.2%—————−31.5%——————
R&D as % of revenue——————————0.3%1.0%0.8%0.7%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

3 of 7 checks passed · June 30, 2026
What it owns · $61m
Short-term assets $37mLonger-term assets $25m
What it owes, and who funded it · $61m
Short-term liabilities $35mLonger-term liabilities $6mShareholders' equity $21m
  • Short-term assets cover short-term liabilities $37m of assets due within a year against $35m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $37m short-term assets against $6m of longer-dated liabilities.
  • More cash than debt $2m of cash against $3m of debt.
  • Debt below 40% of shareholders' equity Debt is 15% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 11% to 15% over five years.
  • A year's operating cash flow covers at least 20% of debt −$10m of operating cash flow against $3m of debt.
  • Operating profit covers interest at least five times over Operating income of −$18m against $2m of interest.

From Cosmos Health Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

22 /100

Weak moat

How hard Cosmos Health's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -30.2% of total assets over 10 years.

  • Pricing power 7 / 20

    Gross margin has been a median 9.2%, moving by 3.1 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -12.4%; its worst year was -37.1%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 8 years, at a median -14.7% of revenue.

  • Discipline 10 / 20

    The diluted share count rose 235.3% over five years; stock-based pay has been a median 1.6% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (27 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: COSM vs HKPDCOSM vs YICOSM vs HSIC

More: Health Care Distributors stocks compared, Health Care sector, rankings of US companies

Figures from Cosmos Health Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cosmos Health Inc.